Helixgate

Helixgate

Uncategorized

Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization

Published

on

This week, Bio-Techne, a provider of life science tools, reagents, and diagnostic product, and Refeyn, a pioneer in mass photometry technology, announced the launch of an integrated workflow for characterizing charge and size variants in bispecific antibodies and biosimilars. 

The workflow combines Bio-Techne’s R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn’s TwoMP mass photometry platform. The combined solution makes it possible for researchers to directly correlate charge heterogeneity with molecular weight and aggregation at single‑molecule resolution in four hours.

“Bispecifics are the fastest growing segment within next‑generation antibodies, but they are very difficult to characterize,” said Gerry Mackay, CEO of Refeyn. That difficulty is due to the structural complexity of these molecules. Incomplete characterization can delay development, increase manufacturing risks, and lead to costly late-stage failures. “This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow,” he said. 

Within the workflow, charge variants are first separated using the MauriceFlex system. They are then analyzed on Refeyn’s TwoMP platform. The system requires a nanogram‑level sample and reveals size distribution and aggregation at single‑molecule resolution. 

Together, the technologies enable direct characterization of aggregation and size within icIEF-resolved charge variants, something which is not accessible with standalone methods. It reduces reliance on multiple tests and supports faster, more efficient process development. 

These capabilities are a boon for customers, according to Will Geist, president of Bio‑Techne’s Protein Sciences Segment. “Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development.” 

The post Bio-Techne, Refeyn Partner on Workflow for Bispecific Antibody, Biosimilar Characterization appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading

Uncategorized

RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Published

on

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.

But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.

Read the rest…

Read More

Continue Reading
Advertisement

Trending